{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:58:37Z","timestamp":1792810717258,"version":"4.5.0"},"reference-count":49,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802525"],"award-info":[{"award-number":["81802525"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["821172817"],"award-info":[{"award-number":["821172817"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172741"],"award-info":[{"award-number":["82172741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Anti-Cancer Association Eyas Project","award":["SACA-CY21A06, SACA-CY21B01"],"award-info":[{"award-number":["SACA-CY21A06, SACA-CY21B01"]}],"id":[{"id":"https:\/\/ror.org\/031vgn537","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HR2020MS-0948"],"award-info":[{"award-number":["Y-HR2020MS-0948"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["20ZR1413100"],"award-info":[{"award-number":["20ZR1413100"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","award":["2020CXJQ03"],"award-info":[{"award-number":["2020CXJQ03"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that develop postnatally in non-lymphoid tissues and are associated with pathological conditions. TLS typically comprise B-cell follicles containing and are encompassed by T- cell zones and dendritic cells. The prognostic and predictive value of TLS in the tumor microenvironment (TME) as potential mediators of antitumor immunity have gained interest. However, the precise relationship between localization and maturation of TLS and the clinical outcome of their presence in clear cell renal cell carcinoma (ccRCC) is yet to be elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemistry and multispectral fluorescence were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. A thorough investigation of the prognostic implications of the TLS heterogeneity in 395 patients with ccRCC from two independent cohorts was conducted. Associations between TLS heterogeneity and immunologic activity were assessed by quantifying the immune cell infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Infiltrated TLS were identified in 34.2% of the ccRCC samples (N=395). These TLS were found to be tumor-proximal, tumor-distal, or both in 37.8%, 74.1%, and 11.9% of the TLS-positive cases, respectively. A higher proportion of early TLS was found in tumor-distal TLS (p=0.016), while tumor-proximal TLS primarily comprised secondary follicle-like structures (p=0.004). In the main study cohort (Fudan University Shanghai Cancer Center, N=290), Kaplan-Meier analyses revealed a significant correlation between the presence of tumor-proximal TLS and improved progression-free survival (PFS, p&lt;0.001) and overall survival (OS, p=0.002). Conversely, the presence of tumor-distal TLS was associated with poor PFS (p=0.02) and OS (p=0.021). These findings were further validated in an external validation set of 105 patients with ccRCC. Notably, the presence of mature TLS (namely secondary follicle-like TLS, with CD23\n                      <jats:sup>+<\/jats:sup>\n                      germinal center) was significantly associated with better clinical outcomes in patients with ccRCC. Furthermore, novel nomograms incorporating the presence of tumor-proximal TLS demonstrated remarkable predictability for the 8-year outcomes of resected ccRCC (area under the curve &gt;0.80). Additionally, ccRCC samples with tumor-distal TLS enriched with primary follicle-like TLS exhibited higher programmed death-ligand 1 tumor-associated macrophages levels and regulatory T cells infiltration in the tumor-distal region, indicative of a suppressive TME.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study for the first time elucidates the impact of TLS localization and maturation heterogeneities on the divergent clinical outcomes of ccRCC. The findings reveal that most TLS in ccRCC are located in the tumor-distal area and are associated with immature, immunosuppressive characterizations. Furthermore, our findings corroborate previous research demonstrating that tumor-proximal TLS were associated with favorable clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-006667","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:30:20Z","timestamp":1701433820000},"page":"e006667","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":112,"title":["Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-9162","authenticated-orcid":false,"given":"Wenhao","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahe","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"},{"name":"School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Rui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihetaimujiang","family":"Anwaier","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Surgery, ShangNan Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"},{"name":"Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2025100310594165000_11.12.e006667.1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2002.01420.x"},{"key":"2025100310594165000_11.12.e006667.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60229-4"},{"key":"2025100310594165000_11.12.e006667.3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jncc.2022.07.001","article-title":"The unique Genomic landscape and Prognostic mutational signature of Chinese clear cell renal cell carcinoma","volume":"2","author":"Xu","year":"2022","journal-title":"Journal of the National Cancer Center"},{"key":"2025100310594165000_11.12.e006667.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"Journal of the National Cancer Center"},{"key":"2025100310594165000_11.12.e006667.5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamaoncol.2018.4604","article-title":"Emerging role of combination Immunotherapy in the first-line treatment of advanced renal cell carcinoma: A review","volume":"5","author":"George","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100310594165000_11.12.e006667.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with Nivolumab plus Ipilimumab versus Sunitinib in first-line treatment of patients with advanced Sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100310594165000_11.12.e006667.7","doi-asserted-by":"crossref","unstructured":"Kim M-C , Jin Z , Kolb R , et al . n.d. Updates on Immunotherapy and immune landscape in renal clear cell carcinoma. Cancers;13:5856. doi:10.3390\/cancers13225856","DOI":"10.3390\/cancers13225856"},{"key":"2025100310594165000_11.12.e006667.8","doi-asserted-by":"crossref","unstructured":"Qu Y , Wu X , Anwaier A , et al . n.d. Proteogenomic characterization of MIT family translocation renal cell carcinoma. Nat Commun;13. doi:10.1038\/s41467-022-34460-w","DOI":"10.1038\/s41467-022-34460-w"},{"key":"2025100310594165000_11.12.e006667.9","doi-asserted-by":"crossref","unstructured":"Qu Y , Feng J , Wu X , et al . n.d. A Proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. Nat Commun;13. doi:10.1038\/s41467-022-29577-x","DOI":"10.1038\/s41467-022-29577-x"},{"key":"2025100310594165000_11.12.e006667.10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2022.12.001","article-title":"Histopathologic and Proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"2025100310594165000_11.12.e006667.11","doi-asserted-by":"crossref","first-page":"785410","DOI":"10.3389\/fcell.2021.785410","article-title":"Prognostic Immunophenotyping clusters of clear cell renal cell carcinoma defined by the unique tumor immune Microenvironment","volume":"9","author":"Xu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025100310594165000_11.12.e006667.12","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.7150\/ijbs.58295","article-title":"Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by Upregulating monocyte\/macrophage infiltration into the clear cell renal cell carcinoma Microenvironment","volume":"17","author":"Xu","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2025100310594165000_11.12.e006667.13","doi-asserted-by":"publisher","DOI":"10.1038\/S41568-020-0285-7"},{"key":"2025100310594165000_11.12.e006667.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.04.016"},{"key":"2025100310594165000_11.12.e006667.15","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.985082","article-title":"Immune signature of tumor infiltrating immune cells in renal cancer","volume":"4","author":"Geissler","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100310594165000_11.12.e006667.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1836-5"},{"key":"2025100310594165000_11.12.e006667.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2926"},{"key":"2025100310594165000_11.12.e006667.18","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary Lymphoid structures predict immune Checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"key":"2025100310594165000_11.12.e006667.19","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary Lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"2025100310594165000_11.12.e006667.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003883","article-title":"Unique characteristics of tertiary Lymphoid structures in kidney clear cell carcinoma: Prognostic outcome and comparison with bladder cancer","volume":"10","author":"Masuda","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100310594165000_11.12.e006667.21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary Lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"2025100310594165000_11.12.e006667.22","doi-asserted-by":"crossref","first-page":"953721","DOI":"10.3389\/fimmu.2022.953721","article-title":"Genomic alteration of MTAP\/Cdkn2A predicts Sarcomatoid differentiation and poor prognosis and modulates response to immune Checkpoint blockade in renal cell carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2025100310594165000_11.12.e006667.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1987"},{"key":"2025100310594165000_11.12.e006667.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2025100310594165000_11.12.e006667.25","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative Ipilimumab plus Nivolumab in Locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"2025100310594165000_11.12.e006667.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2155-6","article-title":"Author correction: tertiary Lymphoid structures improve Immunotherapy and survival in Melanoma","volume":"580","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"2025100310594165000_11.12.e006667.27","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.7150\/ijbs.74647","article-title":"Tumor-associated macrophage-derived Chemokine Ccl5 facilitates the progression and immunosuppressive tumor Microenvironment of clear cell renal cell carcinoma","volume":"18","author":"Xu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2025100310594165000_11.12.e006667.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33080-8","article-title":"A pilot study of Neoadjuvant combination of anti-PD-1 Camrelizumab and Vegfr2 inhibitor Apatinib for locally advanced Resectable oral squamous cell carcinoma","volume":"13","author":"Ju","year":"2022","journal-title":"Nat Commun"},{"key":"2025100310594165000_11.12.e006667.29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006425","article-title":"Localization and density of tertiary Lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100310594165000_11.12.e006667.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1342"},{"key":"2025100310594165000_11.12.e006667.31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300872"},{"key":"2025100310594165000_11.12.e006667.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.003"},{"key":"2025100310594165000_11.12.e006667.33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803424"},{"key":"2025100310594165000_11.12.e006667.34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1378844","article-title":"Maturation of tertiary Lymphoid structures and recurrence of stage II and III colorectal cancer","volume":"7","author":"Posch","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100310594165000_11.12.e006667.35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.698604","article-title":"Tumor-associated tertiary Lymphoid structures: from basic and clinical knowledge to therapeutic manipulation","volume":"12","author":"Domblides","year":"2021","journal-title":"Front Immunol"},{"key":"2025100310594165000_11.12.e006667.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0457-0"},{"key":"2025100310594165000_11.12.e006667.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6"},{"issue":"10 Suppl","key":"2025100310594165000_11.12.e006667.38","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/cncr.24238","article-title":"Complexity of tumor vasculature in clear cell renal cell carcinoma","volume":"115","author":"Qian","year":"2009","journal-title":"Cancer"},{"key":"2025100310594165000_11.12.e006667.39","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.145"},{"key":"2025100310594165000_11.12.e006667.40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/07357907.2022.2136684","article-title":"Tertiary Lymphoid structures, immune response, and Prognostic relevance in non-small cell lung cancer","volume":"41","author":"Giatromanolaki","year":"2023","journal-title":"Cancer Invest"},{"key":"2025100310594165000_11.12.e006667.41","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","article-title":"The Prognostic significance of peritumoral tertiary Lymphoid structures in breast cancer","volume":"68","author":"Sofopoulos","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100310594165000_11.12.e006667.42","doi-asserted-by":"crossref","unstructured":"Zhang F-P , Zhu K , Zhu T-F , et al . n.d. Intra-Tumoral secondary Follicle-like tertiary Lymphoid structures are associated with a superior prognosis of overall survival of Perihilar Cholangiocarcinoma. Cancers;14:6107. doi:10.3390\/cancers14246107","DOI":"10.3390\/cancers14246107"},{"key":"2025100310594165000_11.12.e006667.43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100310594165000_11.12.e006667.44","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00432-019-02879-2","article-title":"The role of PD-1\/PD-L1 axis and macrophage in the progression and treatment of cancer","volume":"145","author":"Cai","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025100310594165000_11.12.e006667.45","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s00262-021-03006-2","article-title":"Multiplexed single-cell pathology reveals the Association of Cd8 T-cell heterogeneity with Prognostic outcomes in renal cell carcinoma","volume":"70","author":"Murakami","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025100310594165000_11.12.e006667.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.03.007"},{"key":"2025100310594165000_11.12.e006667.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004803","article-title":"Clinical outcome following Checkpoint therapy in renal cell carcinoma is associated with a burst of activated Cd8 T cells in blood","volume":"10","author":"Carlisle","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100310594165000_11.12.e006667.48","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3836"},{"key":"2025100310594165000_11.12.e006667.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic Cd40 therapy induces tertiary Lymphoid structures but impairs responses to Checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:59:57Z","timestamp":1759514397000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/jitc-2023-006667"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006667","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}